Fundamentals Overview
DexCom, Inc. is near the low of its 52-week range with moderate valuation, trending downward today.
Valuation moderate
Intrinsic value (DCF)
-46.3% downside vs price
Profitability
Risk (Beta)
1.56 — higher vol
Earnings & growth
BullzEye Analysis
Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B+
Pressures (Sell):
DCF 46.3% downside vs price · 3M vs S&P 500: -14% · 3M vs Healthcare sector: -7.2% · Beta 1.56 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: mixed. Current institutional positions: Buy: 17, Equal Weight: 2, Neutral: 1, Outperform: 4, Overweight: 4, Underweight: 2.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $33.02; current price is $61.54. That’s a -46.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 29.35 |
| DCF value (model) | $33.02 (-46.3% vs price) |
| PEG (TTM) | 0.65 |
| P/B (TTM) | 8.67 |
| P/S (TTM) | 5.15 |
| P/FCF (TTM) | 22.28 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.88 |
| Quick Ratio (TTM) | 1.59 |
| Cash Ratio (TTM) | 0.43 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 17.94% |
| Gross margin (TTM) | 60.1% |
| Operating margin (TTM) | 19.56% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for DXCM.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Citigroup | maintain | Buy | Buy | 2026-03-11 |
| BTIG | maintain | Buy | Buy | 2026-03-09 |
| BTIG | maintain | Buy | Buy | 2026-02-25 |
| Truist Securities | maintain | Buy | Buy | 2026-02-17 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-13 |
| Barclays | maintain | Underweight | Underweight | 2026-02-13 |
| Mizuho | maintain | Outperform | Outperform | 2026-02-13 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-02-13 |
| BTIG | maintain | Buy | Buy | 2026-02-13 |
| Barclays | downgrade | Equal Weight | Underweight | 2026-01-12 |
| Bernstein | maintain | Outperform | Outperform | 2026-01-09 |
| Mizuho | maintain | Outperform | Outperform | 2025-12-17 |
| Citigroup | maintain | Buy | Buy | 2025-12-11 |
| Morgan Stanley | upgrade | Equal Weight | Overweight | 2025-12-02 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-10 |
| Argus Research | maintain | Buy | Buy | 2025-11-07 |
| UBS | maintain | Buy | Buy | 2025-11-03 |
| Truist Securities | maintain | Buy | Buy | 2025-11-03 |
| Barclays | maintain | Equal Weight | Equal Weight | 2025-11-03 |
| TD Cowen | maintain | Buy | Buy | 2025-10-31 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-10-31 |
| RBC Capital | maintain | Outperform | Outperform | 2025-10-31 |
| Canaccord Genuity | maintain | Buy | Buy | 2025-10-31 |
| BTIG | maintain | Buy | Buy | 2025-10-31 |
| JP Morgan | maintain | Neutral | Neutral | 2025-10-31 |
| Citigroup | maintain | Buy | Buy | 2025-10-31 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-10-31 |
| Truist Securities | maintain | Buy | Buy | 2025-10-15 |
| Citigroup | maintain | Buy | Buy | 2025-10-07 |
| Goldman Sachs | maintain | Buy | Buy | 2025-10-01 |